Patents by Inventor Pieter Hadewijn Van Der Graaf

Pieter Hadewijn Van Der Graaf has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150072995
    Abstract: A composition comprising a selective oxytocin antagonist for use in the treatment and/or prevention of a male ejaculatory disorder; which selective oxytocin antagonist is optionally admixed with a pharmaceutically acceptable carrier, diluent or excipient.
    Type: Application
    Filed: September 24, 2014
    Publication date: March 12, 2015
    Applicant: Ixchelsis Limited
    Inventors: Alasdair Mark Naylor, Rachel Jane Russell, Stephen Derek Albert Street, Kim-Wah Tang, Pieter Hadewijn Van Der Graaf, Christopher Peter Wayman
  • Publication number: 20110107442
    Abstract: A composition comprising a selective oxytocin antagonist for use in the treatment and/or prevention of a male ejaculatory disorder; which selective oxytocin antagonist is optionally admixed with a pharmaceutically acceptable carrier, diluent or excipient.
    Type: Application
    Filed: January 10, 2011
    Publication date: May 5, 2011
    Inventors: Alasdair Mark Naylor, Rachel Jane Russell, Stephen Derek Albert Street, Kim-Wah Tang, Pieter Hadewijn Van Der Graaf, Christopher Peter Wayman
  • Publication number: 20090175793
    Abstract: A composition comprising a selective oxytocin antagonist for use in the treatment and/or prevention of a male ejaculatory disorder; which selective oxytocin antagonist is optionally admixed with a pharmaceutically acceptable carrier, diluent or excipient.
    Type: Application
    Filed: December 19, 2008
    Publication date: July 9, 2009
    Inventors: Alasdair Mark Naylor, Rachel Jane Russell, Stephen Derek Albert Street, Kim-Wah Tang, Pieter Hadewijn Van Der Graaf, Christopher Peter Wayman
  • Patent number: 7432299
    Abstract: Use of an alpha-2-delta ligand, or a pharmaceutically acceptable derivative thereof, for the manufacture of a medicament for the treatment of premature ejaculation.
    Type: Grant
    Filed: December 2, 2003
    Date of Patent: October 7, 2008
    Assignee: Pfizer Inc.
    Inventors: Charles Price Taylor, Jr., Andrew John Thorpe, Pieter Hadewijn Van Der Graaf, Christopher Peter Wayman, David Juergen Wustrow
  • Publication number: 20040176456
    Abstract: Use of an alpha-2-delta ligand, or a pharmaceutically acceptable derivative thereof, for the manufacture of a medicament for the treatment of premature ejaculation.
    Type: Application
    Filed: December 2, 2003
    Publication date: September 9, 2004
    Inventors: Charles Price Taylor, Andrew John Thorpe, Pieter Hadewijn Van Der Graaf, Christopher Peter Wayman, David Juergen Wustrow
  • Publication number: 20040087561
    Abstract: Bombesin receptor antagonists have been found to be useful in the treatment of sexual dysfunction in both males and females. They may be selective BB1 antagonists or mixed BB1/BB2 antagonists. Combinations are disclosed of bombesin receptor antagonists with a range of other active compounds, for example PDE5 inhibitors, NEP inhibitors and lasofoxifene.
    Type: Application
    Filed: December 4, 2003
    Publication date: May 6, 2004
    Inventors: Maria Isabel Gonzalez, Michael Higginbottom, Alisdair MArk Naylor, Robert Denham Pinnock, Martyn Clive Pritchard, Herman Thijs Stock, Pieter Hadewijn Van Der Graaf, Christopher Peter Wayman
  • Publication number: 20030229001
    Abstract: A composition comprising a selective oxytocin antagonist for use in the treatment and/or prevention of a male ejaculatory disorder; which selective oxytocin antagonist is optionally admixed with a pharmaceutically acceptable carrier, diluent or excipient.
    Type: Application
    Filed: January 24, 2003
    Publication date: December 11, 2003
    Applicant: Pfizer Inc.
    Inventors: Alasdair Mark Naylor, Rachel Jane Russell, Stephen Derek Albert Street, Kim-Wah Tang, Pieter Hadewijn Van Der Graaf, Christopher Peter Wayman
  • Publication number: 20030119714
    Abstract: The use of an inhibitor of a neuropeptide Y (NPY), preferably of a NPY Y1 receptor, which inhibitor is selective for an NPY or NPY Y1 receptor associated with male genitalia, in the preparation/manufacture of a medicament for the treatment or prevention of male erectile dysfunction (MED).
    Type: Application
    Filed: December 12, 2001
    Publication date: June 26, 2003
    Inventors: Alasdair Mark Naylor, Pieter Hadewijn Van Der Graaf, Christopher Peter Wayman
  • Publication number: 20020169101
    Abstract: Bombesin receptor antagonists have been found to be useful in the treatment of sexual dysfunction in both males and females. They may be selective BB1 antagonists or mixed BB1/BB2 antagonists. Combinations are disclosed of bombesin receptor antagonists with a range of other active compounds, for example PDE5 inhibitors, NEP inhibitors and lasofoxifene.
    Type: Application
    Filed: November 15, 2001
    Publication date: November 14, 2002
    Inventors: Maria Isabel Gonzalez, Michael Higginbottom, Herman Thijs Stock, Martyn Clive Pritchard, Robert Denham Pinnock, Pieter Hadewijn Van Der Graaf, Alisdair Mark Naylor, Christopher Peter Wayman
  • Publication number: 20020028799
    Abstract: The present invention relates to the use of neutral endopeptidase inhibitors (NEPi) and a combination of NEPi and phosphodiesterase type 5 (PDE5) inhibitor for the treatment of male sexual dysfunction, in particular MED.
    Type: Application
    Filed: June 29, 2001
    Publication date: March 7, 2002
    Inventors: Alasdair Mark Naylor, Pieter Hadewijn Van Der Graaf, Christopher peter Wayman